TD Asset Management’s Travere Therapeutics TVTX Stock Holding History

TD Asset Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.1M	Buy	19,330 +1,796	+10%	+$79.6K	﹤0.01%	1077
2026 Q1	$521K	Buy	+17,534	New	+$524K	﹤0.01%	1169
2024 Q4	–	Sell	-71,800	Closed	-$1.01M	–	1402
2024 Q3	$1.01M	Buy	+71,800	New	+$748K	﹤0.01%	1183
2018 Q1	–	Sell	-10,800	Closed	-$228K	–	1372
2017 Q4	$228K	Sell	10,800 -2,600	-19%	-$59.4K	﹤0.01%	1291
2017 Q3	$334K	Hold	13,400	–	–	﹤0.01%	1223
2017 Q2	$260K	Sell	13,400 -8,200	-38%	-$149K	﹤0.01%	1278
2017 Q1	$399K	Sell	21,600 -3,277	-13%	-$64.1K	﹤0.01%	1265
2016 Q4	$471K	Sell	24,877 -1,323	-5%	-$27.1K	﹤0.01%	1197
2016 Q3	$586K	Buy	26,200 +5,300	+25%	+$101K	﹤0.01%	1140
2016 Q2	$372K	Hold	20,900	–	–	﹤0.01%	1206
2016 Q1	$285K	Sell	20,900 -1,200	-5%	-$18.2K	﹤0.01%	1237
2015 Q4	$426K	Hold	22,100	–	–	﹤0.01%	1143
2015 Q3	$448K	Buy	22,100 +600	+3%	+$17.8K	﹤0.01%	1095
2015 Q2	$713K	Hold	21,500	–	–	﹤0.01%	1035
2015 Q1	$515K	Buy	+21,500	New	+$328K	﹤0.01%	1106

Other funds holding TVTX

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

TD Asset Management's TVTX Position: Q2 2026 in Review

TD Asset Management increased its Travere Therapeutics (TVTX) stake by 10% in Q2 2026, buying an estimated $79.6K and bringing the position to 19,330 shares worth $1.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1077.

TD Asset Management first reported a position in TVTX in Q1 2015 and has held it in 15 quarters since. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

TD Asset Management held 19,330 shares of Travere Therapeutics worth $1.1M as of Q2 2026.
TD Asset Management bought 1,796 Travere Therapeutics shares in Q2 2026, an estimated $79.6K.
Travere Therapeutics made up ﹤0.01% of TD Asset Management's portfolio in Q2 2026, its #1077 holding.
TD Asset Management first reported a position in Travere Therapeutics in Q1 2015 and has held it in 15 quarters since.
321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on TD Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.